• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer

    2016-03-24 10:46:02ZhengYangLuYuZheWang
    Chinese Journal of Cancer Research 2016年1期

    Zheng Yang*, Lu Yu*, Zhe Wang

    1State Key Laboratory of Cancer Biology, Department of Pathology, Xi Jing Hospital, Xi’an 710032, China;2The First Cadet Brigade, Fourth Military Medical University, Xi’an 710032, China

    *These authors contributed equally to this work.

    Correspondence to: Prof. Zhe Wang. State Key Laboratory of Cancer Biology, Department of Pathology, Xi Jing Hospital, Fourth Military Medical University, Xi’an 710032, China. Email: zhwang@fmmu.edu.cn.

    ?

    PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer

    Zheng Yang1,2*, Lu Yu1*, Zhe Wang1

    1State Key Laboratory of Cancer Biology, Department of Pathology, Xi Jing Hospital, Xi’an 710032, China;2The First Cadet Brigade, Fourth Military Medical University, Xi’an 710032, China

    *These authors contributed equally to this work.

    Correspondence to: Prof. Zhe Wang. State Key Laboratory of Cancer Biology, Department of Pathology, Xi Jing Hospital, Fourth Military Medical University, Xi’an 710032, China. Email: zhwang@fmmu.edu.cn.

    Abstract:The incidence of prostate cancer (PCa) is rising steadily among males in many countries. Serum prostate-specific antigen (PSA) is widely applied to clinical diagnosis and screening of PCa. However, the so-called grey area of PSA levels 4.0–10.0 ng/mL has a low specificity of 25–40% resulting in a high rate of negative biopsy and overtreatment. So in order to treat PCa patients in early stage, there is an urgent need for new biomarkers in PCa diagnosis. The PCA3 gene, a non-coding RNA (ncRNA) that is highly expressed in prostate cancer (PCa) cells, has been identified as a molecular biomarkers to detect PCa, of which PCA3 has already under clinical application. PCA3 is strongly overexpressed in malignant prostate tissue compared to benign or normal adjacent one. Newly, PCA3 is considered to be a promising biomarker in clinical diagnosis and targeted therapy. The diagnostic signifi cance of PCA3, however, is awaiting further researches. Moreover, it has been demonstrated recently that TMPRSS2-ERG gene fusion is identifi ed as the predominant genetic change in patients diagnosed with PCa. Recent study revealed that combination of the PCA3 and TMPRSS2-ERG gene fusion test optimizes PCa detection compared with that of single biomarker, which would lead to a considerable reduction of the number of prostate biopsies. In this review, we focused on the potential use of PCA3 and TMPRSS2-ERG gene fusion detection in the diagnosis of PCa.

    Keywords:Prostate; prostate cancer antigen 3 (PCA3); TMPRSS2-ERG gene fusion; prostate cancer (PCa); biomarker

    Submitted Apr 26, 2015. Accepted for publication Jan 19, 2016.

    View this article at: http://dx.doi.org/10.3978/j.issn.1000-9604.2016.01.05

    Introduction

    Prostate cancer (PCa) has become as a leading causes of cancer death in many countries among males (1). In recent year, the incidence of PCa have showed an obvious growth trend in China. PCa is becoming urinary tract malignant tumor that impacts Chinese men’s health seriously.

    As a n invasive testing method, the histopathologic evaluation of prostate biopsies is served as the golden standard for the diagnosis of PCa. At the early stage, PCa does not present with patent clinical manifestation. The decision of prostate biopsies implement relies largely on serum prostate-specific antigen (PSA) testing and digital rectal examination (DRE) (2). The limitations of PSA as PCa early detection biomarker are sound discussed, and the controversy of its use in the screening setting were highlighted recently (3). The so-called grey area of PSA levels 4.0–10.0 ng/mL has a low specificity of 25–40% resulting in a high rate of negative biopsy (4). In addition, DRE is very subjective leading to numerous false positive results and many unnecessary biopsies. Thus, there is an urgent need for new biomarkers in the diagnosis of PCa.

    With significant advances in genetics and cell biology, numerous PCa biomarkers have been found recently. Increasing evidence has shown that long non-coding RNAs, such as pro state cancer antigen 3 (PCA3) might be servedas promising biomarkers in the diagnosis of PCa. PCA3 was initially known as DD3, located on chromosome 9q21-22. The PCA3 gene, widely studied in recent years, is probably one of the first biomarkers which already under clinical application. Highly overexpression of PCA3 in PCa tissue was found to be a potential non-invasively prediction of prostate biopsy which might be a promising biomarker in clinical diagnosis (5). The Clinical has focused mainly on an assay about transcription-mediated amplification (TMA, Progensa PCA3 test). Authoritatively, the assay has been approved by the US Food and Drug Administration (FDA) and is Community European (CE) marked for assessing the risk of PCa in men who has a previous negative biopsy (6).

    One of the earliest genetic variation, ERG oncogene, identifi ed as a transcription factor of ETS family, located on chromosomal band 21q22 is overexpressed in over 50% of PCa (7). Transmembrane protease, serine 2 (TMP RSS2), a prostate-specific and androgen regulated gene, locates very closer to ERG on the same chromosome. It has been identified that the overexpression of ERG in major PCa was driven by fusing with TMPRSS2 (8). In recent studies, TMP RSS2-ERG gene fusion is the pervasive variant in about 40% to 70% PCa (9). Due to various detecting method, it is expected that TMPRSS2-ERG gene fusion might be a promising biomarker of PCa.

    Probably, urine and venous blood specimens after prostate massage is the most easily obtained specimen for biomarkers detection. It could be collected non-invasively and is available in large amount. Urine markers are especially attractive when the prostate in the early stage disease and setting of screening (10). We have searched the literatures by using the key words PCA3, TMPRSS2, ERG, and PCa, and reviewed all the published papers. We focus on the potential value of the PCA3 and TMPRSS2-ERG gene fusion, especially for their ability to calculate patient risk with ever negative biopsy for the occult cancer.

    PCA3: molecular science and clinical use

    PCA3, named as differential display clone 3 (DD3) initially, found by Bus semakers et al. in 1999, was specifically expressed in PCa tissue from 10- to 100-fold in relation to non-neoplastic prostatic surrounding tissue in 53 of 56 patients treated with radical prostatectomy (11). PCA3 is a non-coding RNA located on chromosome 9q21-22, contains a high density of stop codons, whose biological function is not well-known. Recent study suggested that PCA3 modulated the transcriptional activity of androgen receptor target genes which might play a role in the control of PCa cell survival (12).

    Since PCA3 was discovered by Bussemakers et al., various methods of the measurement has developed, such as Progensa TM PCA3 test, which promote the clinical applicability of PCA3 in the diagnosis of PCA. To evaluate the potential usefulness of PCA3 as a diagnostic marker for PCa, a time-resolved fluoresce-based quantitative RT-PCR assay has been developed. Urine specimens were collected after prostate massage. It has been reported that compared with normal prostate tissue, PCA3 overexpression is 66-fold up-regulated in PCa tissue (13). It also suggested that an average 11-fold up-regulation in prostate tissue specimens containing fewer than 10% PCa cells (13), which means that polymerase chain reaction assay can detected a few cancer cells in a background of normal cells, prompted the potential assay of PCA3 in urine.

    In the study accompanying this review, Merola et al. report on PCA3 in PCa and tumor aggressiveness detection on 407 high-risk patients (3). The PCA3 test showed the best diagnostic function when compared with tPSA and f/tPSA, promoting the choice of high-risk patients that may benefit from the operation of a traumatic prostatic biopsy. In addition, the PCA3 test could show a prognostic value, which higher PCA3 score values would relate to greater tumor aggressiveness.

    PCA3 guides the decision making of prostate biopsy

    The golden standard for the diagnosis of PCa is the histopathologic evaluation of prostate biopsy, which is an invasive testing method. The decision of implementing prostate biopsy relies on PSA testing and DRE. Although raised levels of serum PSA are suggestive of PCa, yet, diagnostic confirmation requires a transrectal prostatic needle biopsy, which is an invasive procedure. Still there is the so-called grey area of PSA levels 4.0–10.0 ng/mL has a low specificity of 25–40% resulting in a high rate of negative biopsy (4). Among those previous negative prostate biopsy, 10–35% can be indentified cancer by a systematic repeat prostate biopsy, which result in a high proportion of unnecessary biopsies (14,15). While making a decision of initial or repeat prostate biopsy, the risk of unnecessary biopsy which leads to complication and patient discomfort, pain, anxiety, waste cost have to be taken into consideration. The PCA3 score is the ratio of PCA3 mRNA to PSA mRNA multiplied by 1,000. Many large-scale multicenterclinical studies have confirmed that the PCA3 score can overcome the disadvantages of the low specificity of the traditional PSA test. Recent data suggested that PCA score is correlated with the positive rate of prostate biopsy (16). It showed that when a PCA3 cutoff score of 35 was used during the fi rst prostate biopsy, the sensitivity and specifi city increased to 82.3% and 89.0% respectively. Compared to using PSA, the best PSA cutoff value of sensitivity and specificity showed only 57.4% and 53.8%, the priority of PCA score is obvious (17-20). An European study suggested that the area under the curve (AUC) of PCA3 was 0.761 and 0.65 in initial and repeat prostate biopsy respectively (16). The synthesis of these finding demonstrated that using PCA3 score at guiding both initial and repeat biopsy has priority over PSA testing.

    Some research suggested that PCA3 has a higher diagnostic accuracy, but strength of evidence was insuf fi cient to conclude that PCA3 testing leads to improve health outcome (21).

    PCA3 and Gleason score

    Histologic differentiation of PCa is closely related to the prognosis, biologic behavior, treatments option and patient outcome. Gleason grading system is used to evaluate the prognosis of PCa based on its microscopic appearance (22). The present results indicated a correlation between PCA3 and Gleason score (23). However, some data suggested that there was no diff erence between the migrated Gleason score tumor group and the group of confirmed Gleason score tumors, thus the ability of PCA3 to predict final Gleason score was limited. In addition, a PCA3 score >35 di d not appear in a multivariate analysis as an independent factor of a Gleason score >7. Consequently, it is blurred of the clinical impact of PCA3 and Gleason score correlation is ambiguous (24).

    Although there are some limitations of PCA3 application, it is still considered as a useful clinical tool in the diagnosis of PCa, especially when the viewpoint of combining PCA3 assay with other markers has been raised up, such as TMPRSS2-ERG gene fusion, another biomarker of PCa (25).

    TMPRSS2-ERG gene fusion in PCa

    ERG gene was identified as a transcription factor of ETS family (26,27), which involved in chromosome translocations in Ewing family of tumors as well as in leukemias. In 2005, frequent overexpression of ERG in PCa was observed (28). Later that year, it was discovered that the mechanism underlying this overexpression was the recurrent genomic rearrangement between the fi rst exon(s) of TMPRSS2 and the ERG oncogenes (29). It had been confirmed that The fu sion of TMPRSS2 and ERG genes appeared in nearly 50% of PCa patients (30,31). TMPRSS2 is an androgen-regulated gene that is preferentially expressed in the prostate (32). TMPRSS2 is located on chromosomal band 21q22. ERG maps also 21q22 in the same orientation, at a distance of approximately 3 Mb. The fusion of the androgen- and prostate-specific regulating sequences and first exon(s) of TMPRSS2 to the coding sequences of ERG resulted in the androgen-regulated overexpression of ERG.

    TMPRS S2-ERG gene fusion in the activation oftra nsforming growth factor beta/smads signaling pathway

    Although the specific role of TMPRSS2-ERG fusion in PCa is not well understood, yet ERG-positive patients have a low rate of high Gleason grade, poor diff erentiation compared to ERG-negative patients (33,34). TMPRSS2-ERG gene fusions may be cancer-initiating, and expressed at both RNA and protein levels in PCa stem cells (34,35). It also has been shown that an anti-epileptic drug targets ERG-positive PCa cells through the activation of tumor suppressors and nuclear receptors (36).

    Recent studies found that it might play an important role in the acitivation of Transforming Growth Factor Beta/Smads Signaling Pathway (37). It is well known that TGF-β signaling pathway involved in cell proliferation, differentiation, migration, adhesion, apoptosis, embryonic development, and is even related to human diseases including cardiovascular, fibrosis, reproductive, wounded healing disorders and cancer (38,39). After TGF-β ligand binding to its receptor, R-Smads (receptor-regulated Smads) including Smad2 and Smad3 protein are phosphorylated, and then form a complex by interacted with Smad4. The complex then translocate into nucleus and bind to target genes.

    It is common to find genetic alteration and recurrent gene fusion between ERG and TMPRSS2 on chromosome 21 in prostate. In these PCa cases, ERG gene expression is significantly upregulated by the androgen-responsive promoter of TMPRSS2. Although the role of TMPRSS2-ERG gene fusion protein in PCa is not well understood, recentresults found that over-expression of ERG may be a useful biomarker of PCa diagnosis.

    TMPRSS2-ERG gene fusion in small cell carcinoma (SCC) of PCa

    SCC, accounts for less than 2.0% of de novo PCa, is a rare variant neuroendocrine tumor of the prostate (40). Compared with prostatic adenocarcinoma, which accounts for most PCas, prostatic SCC shows obvious difference in clinicopathologic features. Most prostati c adenocarcinomas hardly have clinical manifestation and can be identifi ed by an increase of PSA. The process of prostatic adenocarcinomas is slow and the metastasis often occurs at advanced stage. Responding well to androgen ablation treatment, patients with prostati c adenocarcinomas can achieve long life expectancy (41).

    On the contrary, patients with prostati c SCC show no increase in PSA. And the disease progresses rapidly with metastasis at very early stage. For the lack of androgen receptor, prostatic SCC shows resistance to androgen ablation (42). SCC can originate in various organs, such as lung, cervix, prostate, urinary bladder, etc., with the lung being the most common origin. As SCCs arising from diff erent organs share similar histologic, immunohistochemical, and ultrastructural features (43-45), it may be difficult to deduce the origin when SCC is observed in the prostate especially after its metastasis. Besides it, most prostatic SCCs lose the prostate-specific immunohistochemical markers, such as prostatic acid phosphatase, PSA, prostate-specific membrane antigen, and protein (44). Therefor e, a specific molecular marker to distinguish the prostatic origin of SCC may be clinically useful.

    Despite the frequent occurrence of ERG gene rearrangements in adenocarcinoma, the incidence of these rearrangements in prostatic SCC is unclear. Recent study found that the presence of ERG rearrangements in nearly half of the prostatic SCCs is a similar rate of rearrangement that found in prostatic acinar carcinomas. Furthermore, the high concordance rate of ERG rearrangement between the SCC and adenocarcinoma components in a given patient supports a common origin for these two subtypes of PCa. The absence of TMPRSS2-ERG gene fusion in bladder or lung SCCs highlighted the utility of detecting TMPRSS2-ERG gene fusion in SCCs of unknown primary for establishing prostatic origin and identified a promising molecular marker for establishing prostatic origin in SCCs of unknown primary (46).

    Evaluation of PCA3 and TMPRSS2- ERG gene fusions as diagnostic biomarkers for PCa

    The gold standard for the diagnosis of (PCa) is based on the histopathologic evaluation of prostate biopsies, an invasive procedure associated with patients’ discomfort, anxiety and severe complications. Because localized PCa often does not present with symptoms, the selection of men qualifying for prostate biopsies relies on serum PSA testing and digital r ectal examination (DRE). However, PSA has a low specifi city resulting in a high negative biopsy rate (47). And DRE is very subjective. A specific biomarker of PCA is required for clinical diagnosis.

    In 2006, the TMPRSS2-ERG gene fusion transcripts were successfully detected in urine samples (48). This urine test had a sensitivity of 37% and a specificity of 93% for the prediction of PCa on prostate biopsy (7). TMPRSS2-ERG had great predictive value to PCA3 and the European Randomised study of Screening for Prostate Cancer (ERSPC) risk calculator parameters for predicting PCa (6).

    Recent st udy shown that both PCA3 and TMPRSS2-ERG fusion had independent additional predictive value for predicting PCa. Recent study suggested that applying this biomarker panel of PCA3 combine with TMPRSS2-ERG fusion to clinical diagnosis could avoid 35% negative prostate biopsies, missing only 10% of the men with PCa with a Gleason score-7 (7). Implementing the novel biomarker panel PCA3 and TMPRSS2-ERG into clinical practice would lead to a considerable reduction of prostate biopsies.

    However, some cohort studies and meta-analysis revealed that TMPRSS2-ERG fusion status was not a strong predictor of PCa recurrence or cancer-specific mortality. The role of TMPRSS2-ERG in PCa pathogenesis and progression is only starting to emerge (49). Recent study proposed prostate health index (PHI) calculated by a mathematical formula combining PSA molecular forms, which also can off er a reduction in unnecessary biopsy (50).

    Conclusions

    Formerly, PCa candidates biopsy selection relies largely on serum PSA testing and digital rectal examination (DRE). However, due to the lack of specificity, new biomarkers of PCa is needed urgently. Unfortunately, PCA3 test also has limitations. For instance, patients with indolent tumors present a low PCA3 score which PCA3 test cannot exclude.

    Since TMPRSS2-ERG gene fusions has been detectedin a significant portion of PCa, it is identified as a potential diagnostic and therapeutic target of PCa, especially in SCC. And recent study showed a great ascendance of biomarker panel combining PCA3 and TMPRSS2-ERG in PCa diagnosis, which may prevail in clinical practice. Therefore, in order to optimize the PCa detection, combining the PCA3 and TMPRSS2-ERG gene fusion test might have applicable diagnostic.

    Acknowledgements

    Funding: This work was supported by the following grants: National Natural Science Foundation of China No. 31571413, 31201037 (to Dr. Yu) and No. 81570180, 81072103 (to Dr. Wang) from the National Natural Science Foundation of China.

    Footnote

    Confl icts of Interest: The authors have no confl icts of interest to declare.

    References

    1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.

    2. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124-37.

    3. Merola R, Tomao L, Antenucci A, et al. PCA3 in prostate cancer and tumor aggressiveness detection on 407 highrisk patients: a National Cancer Institute experience. J Exp Clin Cancer Res 2015;34:15.

    4. Roddam AW, Duff y MJ, Hamdy FC, et al. Use of prostate-specifi c antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99; discussion 398-9.

    5. Jung M, Xu C, Spethmann J, et al. Re: Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-16. Eur Urol 2004;46:271-2.

    6. Tomlins SA. Urine PCA3 and TMPRSS2:ERG using cancer-specifi c markers to detect cancer. Eur Urol 2014;65:543-5.

    7. Hessels D, Smit FP, Verhaegh GW, et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007;13:5103-8.

    8. Tomlins SA, Bjartell A, Chinnaiyan AM, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 2009;56:275-86.

    9. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007;31:882-8.

    10. Locke JA, Black PC. Next generation biomarkers in prostate cancer. Front Biosci (Landmark Ed) 2016;21:328-42.

    11. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specifi c gene, highly overexpressed in prostate cancer. Cancer Res 1999;59:5975-9.

    12. Ferreira LB, Palumbo A, de Mello KD, et al. PCA3 noncoding RNA is involved in the control of prostatecancer cell survival and modulates androgen receptor signaling. BMC Cancer 2012;12:507.

    13. Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-15; discussion 15-6.

    14. Djavan B, Zlotta A, Remzi M, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 2000;163:1144-8; discussion 1148-9.

    15. Roehl KA, Antenor JA, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002;167:2435-9.

    16. Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179:1587-92.

    17. Ochiai A, Okihara K, Kamoi K, et al. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy. BJU Int 2013;111:928-33.

    18. Salagierski M, Mulders P, Schalken JA. Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort. Anticancer Res 2013;33:553-7.

    19. Pepe P, Aragona F. Prostate cancer detection rate at repeat saturation biopsy: PCPT risk calculator versus PCA3 score versus case-fi nding protocol. Can J Urol 2013;20:6620-4.

    20. Goode RR, Marshall SJ, Duff M, et al. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients. Prostate 2013;73:48-53.

    21. Bradley LA, Palomaki GE, Gutman S, et al. Comparative eff ectiveness review: prostate cancer antigen 3 testing forthe diagnosis and management of prostate cancer. J Urol 2013;190:389-98.

    22. Epstein JI, Pound CR, Partin AW, et al. Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol 1998;160:97-100; discussion 101.

    23. Miller K. Words of wisdom. Re: PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. Whitman EJ, Groskopf J, Ali A, et al. J Urol 2008;180:1975-8; discussion 1978-9. Eur Urol 2009;56:218-9.

    24. Durand X, Xylinas E, Radulescu C, et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int 2012;110:43-9.

    25. Leyten GH, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014;65:534-42.

    26. Rao VN, Papas TS, Reddy ES. erg, a human etsrelated gene on chromosome 21: alternative splicing, polyadenylation, and translation. Science 1987;237:635-9. 27. Reddy ES, Rao VN, Papas TS. The erg gene: a human gene related to the ets oncogene. Proc Natl Acad Sci U S A 1987;84:6131-5.

    28. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005;24:3847-52.

    29. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions defi ne a third molecular subtype of prostate cancer. Cancer Res 2006;66:3396-400.

    30. Furusato B, Gao CL, Ravindranath L, et al. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008;21:67-75.

    31. Shah RB, Chinnaiyan AM. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications. Adv Anat Pathol 2009;16:145-53.

    32. Hermans KG, Boormans JL, Gasi D, et al. Overexpression of prostate-specifi c TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 2009;15:6398-403.

    33. Hu Y, Dobi A, Sreenath T, et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 2008;14:4719-25.

    34. Klezovitch O, Risk M, Coleman I, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A 2008;105:2105-10.

    35. Polson ES, Lewis JL, Celik H, et al. Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells. Nat Commun 2013;4:1623.

    36. Fortson WS, Kayarthodi S, Fujimura Y, et al. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and aff ect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol 2011;39:111-9.

    37. Fang J, Xu H, Yang C, et al. Molecular Mechanism of Activation of Transforming Growth Factor Beta/Smads Signaling Pathway in Ets Related Gene-Positive Prostate Cancers. J Pharm Sci Pharmacol 2014;1:82-85.

    38. de Caestecker MP, Piek E, Roberts AB. Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 2000;92:1388-402.

    39. Tian M, Neil JR, Schiemann WP. Transforming growth factor-β and the hallmarks of cancer. Cell Signal 2011;23:951-62.

    40. Palmgren JS, Karavadia SS, Wakefi eld MR. Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol 2007;34:22-9.

    41. Wang HT, Yao YH, Li BG, et al. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. J Clin Oncol 2014;32:3383-90.

    42. Stein ME, Bernstein Z, Abacioglu U, et al. Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications--a retrospective study of 30 patients from the rare cancer network. Am J Med Sci 2008;336:478-88.

    43. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002;26:1184-97.

    44. Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008;32:65-71.

    45. Yao JL, Madeb R, Bourne P, et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol 2006;30:705-12.

    46. Lotan TL, Gupta NS, Wang W, et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011;24:820-8.

    47. Stephan C, Schnorr D, Loening SA, et al. Re: RoddamAW, Duff y MJ, Hamdy FC, et al. Use of prostate-specifi c antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99. Eur Urol 2005;48:1059-60; author reply 1060-1.

    48. Laxman B, Tomlins SA, Mehra R, et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006;8:885-8.

    49. Pettersson A, Graff RE, Bauer SR, et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012;21:1497-509.

    50. Bruzzese D, Mazzarella C, Ferro M, et al. Prostate health index vs percent free prostate-specifi c antigen for prostate cancer detection in men with "gray" prostate-specifi c antigen levels at fi rst biopsy: systematic review and metaanalysis. Transl Res 2014;164:444-51.

    Cite this article as: Yang Z, Yu L, Wang Z. PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer. Chin J Cancer Res 2016;28(1):65-71. doi: 10.3978/j.issn.1000-9604.2016.01.05

    doi:10.3978/j.issn.1000-9604.2016.01.05

    亚洲婷婷狠狠爱综合网| 春色校园在线视频观看| 久久久久国产精品人妻一区二区| 国产野战对白在线观看| 欧美日本中文国产一区发布| 亚洲激情五月婷婷啪啪| av片东京热男人的天堂| 午夜日韩欧美国产| 精品99又大又爽又粗少妇毛片| 精品人妻在线不人妻| 中文字幕人妻丝袜一区二区 | 欧美xxⅹ黑人| 看非洲黑人一级黄片| 亚洲一级一片aⅴ在线观看| 校园人妻丝袜中文字幕| 亚洲五月色婷婷综合| 久久久a久久爽久久v久久| 亚洲久久久国产精品| 成人毛片a级毛片在线播放| 日本wwww免费看| 久久热在线av| 一区二区三区激情视频| 亚洲精品一二三| 中文字幕人妻丝袜制服| 十分钟在线观看高清视频www| 国产综合精华液| 丰满少妇做爰视频| 最近手机中文字幕大全| 女人被躁到高潮嗷嗷叫费观| 国产成人午夜福利电影在线观看| 18在线观看网站| 精品午夜福利在线看| 亚洲成人手机| 伊人久久大香线蕉亚洲五| 久久亚洲国产成人精品v| 国产av码专区亚洲av| 日本色播在线视频| 午夜免费鲁丝| 999精品在线视频| 免费少妇av软件| 亚洲av电影在线进入| 国产一区二区三区av在线| 国产精品 欧美亚洲| 亚洲国产最新在线播放| videos熟女内射| 九草在线视频观看| 最新中文字幕久久久久| 丝袜美足系列| 国产乱人偷精品视频| 亚洲国产日韩一区二区| 久久免费观看电影| 男人操女人黄网站| 久久久久人妻精品一区果冻| 亚洲av综合色区一区| 秋霞伦理黄片| 精品少妇黑人巨大在线播放| 久久人妻熟女aⅴ| 午夜日本视频在线| 婷婷色综合大香蕉| 日日摸夜夜添夜夜爱| 99热全是精品| 欧美黄色片欧美黄色片| 在线观看免费日韩欧美大片| 天美传媒精品一区二区| 国产精品一二三区在线看| 精品人妻一区二区三区麻豆| 国产熟女欧美一区二区| 免费播放大片免费观看视频在线观看| 看免费av毛片| 久久精品久久久久久久性| 久久久精品免费免费高清| 黄频高清免费视频| www.精华液| 老司机亚洲免费影院| 日本91视频免费播放| 精品酒店卫生间| 麻豆av在线久日| 在线观看三级黄色| 国产老妇伦熟女老妇高清| 欧美精品高潮呻吟av久久| 欧美最新免费一区二区三区| 一区在线观看完整版| 亚洲欧洲精品一区二区精品久久久 | 热re99久久精品国产66热6| 久久婷婷青草| 国产极品天堂在线| 色视频在线一区二区三区| 99热全是精品| 考比视频在线观看| 超色免费av| 国产人伦9x9x在线观看 | 成人黄色视频免费在线看| 成人影院久久| 亚洲av综合色区一区| 午夜福利,免费看| 2022亚洲国产成人精品| 久久综合国产亚洲精品| 中文字幕亚洲精品专区| 国产高清不卡午夜福利| 777米奇影视久久| 欧美人与性动交α欧美软件| 精品人妻在线不人妻| 伊人亚洲综合成人网| 国产成人精品婷婷| 国产日韩欧美视频二区| 捣出白浆h1v1| 五月伊人婷婷丁香| 久久午夜福利片| 欧美 日韩 精品 国产| 成年人免费黄色播放视频| 国产 一区精品| 青青草视频在线视频观看| 黄网站色视频无遮挡免费观看| 亚洲人成网站在线观看播放| 2022亚洲国产成人精品| 日日爽夜夜爽网站| 丝袜喷水一区| av网站免费在线观看视频| 大片电影免费在线观看免费| 久久久精品区二区三区| 伦理电影大哥的女人| 视频区图区小说| 美女福利国产在线| 波多野结衣av一区二区av| 香蕉丝袜av| 色吧在线观看| 亚洲欧美清纯卡通| 赤兔流量卡办理| 午夜日本视频在线| 久久国产亚洲av麻豆专区| 纯流量卡能插随身wifi吗| 久久久久久久久久久免费av| 日日撸夜夜添| 亚洲精品第二区| 1024香蕉在线观看| 日韩中字成人| 亚洲婷婷狠狠爱综合网| 国产xxxxx性猛交| 国产福利在线免费观看视频| 中国国产av一级| 亚洲三区欧美一区| 女人久久www免费人成看片| 亚洲欧美成人综合另类久久久| 嫩草影院入口| 丝袜喷水一区| 电影成人av| 国产视频首页在线观看| 中文字幕亚洲精品专区| 亚洲成人av在线免费| 99久久中文字幕三级久久日本| 日韩免费高清中文字幕av| 一级爰片在线观看| 久久免费观看电影| 免费观看无遮挡的男女| 在线观看一区二区三区激情| 国产精品 国内视频| 国产高清国产精品国产三级| 欧美成人午夜免费资源| 精品人妻偷拍中文字幕| 久久青草综合色| 熟妇人妻不卡中文字幕| 亚洲精品aⅴ在线观看| 一级毛片电影观看| 女人被躁到高潮嗷嗷叫费观| 制服丝袜香蕉在线| 免费av中文字幕在线| 久久精品久久久久久久性| 91精品三级在线观看| 看非洲黑人一级黄片| 久久精品国产综合久久久| 亚洲三区欧美一区| 亚洲国产精品999| 69精品国产乱码久久久| 日本欧美国产在线视频| 亚洲在久久综合| 最新中文字幕久久久久| 国产精品熟女久久久久浪| 成人午夜精彩视频在线观看| 免费在线观看黄色视频的| 午夜福利影视在线免费观看| 国产精品国产av在线观看| 免费观看a级毛片全部| 精品少妇内射三级| 日韩欧美一区视频在线观看| 欧美精品一区二区免费开放| 最近手机中文字幕大全| 欧美变态另类bdsm刘玥| 久久久久久伊人网av| 亚洲欧美中文字幕日韩二区| 一本一本久久a久久精品综合妖精 国产伦在线观看视频一区 | 春色校园在线视频观看| 高清视频免费观看一区二区| 久久久久视频综合| 免费看av在线观看网站| 日本-黄色视频高清免费观看| 欧美少妇被猛烈插入视频| 老汉色∧v一级毛片| 国产男女超爽视频在线观看| 欧美精品av麻豆av| 极品少妇高潮喷水抽搐| 街头女战士在线观看网站| 国产精品久久久久久av不卡| 久久久精品免费免费高清| 成人黄色视频免费在线看| 一级毛片我不卡| 秋霞伦理黄片| 亚洲综合色惰| 婷婷色av中文字幕| 国产福利在线免费观看视频| 久久韩国三级中文字幕| 少妇被粗大的猛进出69影院| 极品人妻少妇av视频| 午夜激情av网站| 久久精品国产亚洲av涩爱| 亚洲国产av影院在线观看| 欧美精品人与动牲交sv欧美| 丝袜美足系列| 久久久久久久亚洲中文字幕| 日韩伦理黄色片| 老司机影院成人| 亚洲国产精品999| 日本vs欧美在线观看视频| 水蜜桃什么品种好| www.av在线官网国产| 爱豆传媒免费全集在线观看| 女性被躁到高潮视频| 黄片小视频在线播放| 国产麻豆69| 欧美日韩av久久| 精品人妻熟女毛片av久久网站| 日韩大片免费观看网站| 亚洲国产成人一精品久久久| 久久久亚洲精品成人影院| 亚洲色图综合在线观看| 午夜免费男女啪啪视频观看| 少妇人妻 视频| 国产精品99久久99久久久不卡 | 午夜av观看不卡| 美国免费a级毛片| 午夜免费男女啪啪视频观看| 日韩三级伦理在线观看| 久久久久久久大尺度免费视频| 中文字幕人妻丝袜制服| av在线播放精品| 国产xxxxx性猛交| 日本色播在线视频| 日韩 亚洲 欧美在线| 国产精品.久久久| 免费久久久久久久精品成人欧美视频| 九九爱精品视频在线观看| 成人毛片60女人毛片免费| 日本av手机在线免费观看| 免费少妇av软件| 免费观看a级毛片全部| 色婷婷久久久亚洲欧美| 国产高清不卡午夜福利| 久久精品久久精品一区二区三区| 日韩欧美一区视频在线观看| 爱豆传媒免费全集在线观看| 伊人久久大香线蕉亚洲五| 天天躁夜夜躁狠狠久久av| 嫩草影院入口| 亚洲精品美女久久av网站| 亚洲国产欧美在线一区| 999久久久国产精品视频| 纵有疾风起免费观看全集完整版| 午夜日韩欧美国产| 欧美日本中文国产一区发布| 国产视频首页在线观看| 久久久国产欧美日韩av| 99香蕉大伊视频| 亚洲国产精品成人久久小说| 国产男女超爽视频在线观看| 亚洲色图综合在线观看| 午夜福利,免费看| xxx大片免费视频| 晚上一个人看的免费电影| 狠狠婷婷综合久久久久久88av| av免费观看日本| 国产亚洲欧美精品永久| 亚洲三级黄色毛片| 亚洲精品aⅴ在线观看| 91在线精品国自产拍蜜月| 亚洲av在线观看美女高潮| 欧美精品一区二区大全| 久久人人爽av亚洲精品天堂| 97在线人人人人妻| 日韩人妻精品一区2区三区| 欧美精品av麻豆av| 黄色 视频免费看| 女性生殖器流出的白浆| 大码成人一级视频| 韩国高清视频一区二区三区| 亚洲成人av在线免费| 爱豆传媒免费全集在线观看| 狂野欧美激情性bbbbbb| 久久精品国产亚洲av涩爱| 一本—道久久a久久精品蜜桃钙片| 色婷婷久久久亚洲欧美| 欧美老熟妇乱子伦牲交| 成人国产麻豆网| 欧美人与性动交α欧美软件| 欧美变态另类bdsm刘玥| 欧美人与性动交α欧美精品济南到 | 91aial.com中文字幕在线观看| 亚洲国产欧美网| 日本欧美视频一区| 一级,二级,三级黄色视频| 亚洲欧洲精品一区二区精品久久久 | 永久网站在线| 久久久久精品久久久久真实原创| 午夜91福利影院| 日韩视频在线欧美| 国产黄色免费在线视频| 久久午夜综合久久蜜桃| 如何舔出高潮| 精品人妻熟女毛片av久久网站| 天堂中文最新版在线下载| 高清av免费在线| 青春草国产在线视频| 大香蕉久久网| 国产一区亚洲一区在线观看| 少妇 在线观看| 亚洲精品美女久久av网站| 色婷婷av一区二区三区视频| 老司机亚洲免费影院| 18禁国产床啪视频网站| 日本wwww免费看| 国产黄色视频一区二区在线观看| 高清视频免费观看一区二区| 国产精品 欧美亚洲| 国产日韩欧美在线精品| 精品久久蜜臀av无| 999久久久国产精品视频| 中文欧美无线码| 人妻少妇偷人精品九色| 叶爱在线成人免费视频播放| 午夜日韩欧美国产| 久久久久国产网址| 亚洲精品久久午夜乱码| 99re6热这里在线精品视频| 精品一区在线观看国产| 少妇被粗大的猛进出69影院| 一级片'在线观看视频| 午夜福利视频在线观看免费| 99热网站在线观看| 新久久久久国产一级毛片| 中文字幕人妻熟女乱码| 女的被弄到高潮叫床怎么办| 日韩中字成人| 亚洲国产成人一精品久久久| 国产精品一国产av| 超碰97精品在线观看| 亚洲av国产av综合av卡| 在线免费观看不下载黄p国产| 最近最新中文字幕大全免费视频 | 精品第一国产精品| 一本一本久久a久久精品综合妖精 国产伦在线观看视频一区 | 午夜精品国产一区二区电影| 欧美人与性动交α欧美精品济南到 | av视频免费观看在线观看| 国产精品人妻久久久影院| 久久精品国产亚洲av天美| 免费观看a级毛片全部| 久久精品久久久久久久性| 国产黄色免费在线视频| 亚洲三区欧美一区| 各种免费的搞黄视频| 黑人巨大精品欧美一区二区蜜桃| 日韩不卡一区二区三区视频在线| 老熟女久久久| 七月丁香在线播放| 国产精品麻豆人妻色哟哟久久| 日韩制服骚丝袜av| 91成人精品电影| 日韩制服骚丝袜av| 国产亚洲av片在线观看秒播厂| 亚洲欧洲国产日韩| 国产在线一区二区三区精| 搡女人真爽免费视频火全软件| 中文字幕亚洲精品专区| 亚洲美女视频黄频| 97在线人人人人妻| 少妇的丰满在线观看| 国产亚洲精品第一综合不卡| 爱豆传媒免费全集在线观看| 男人添女人高潮全过程视频| 日韩av免费高清视频| 亚洲第一av免费看| 亚洲国产欧美在线一区| 日韩一区二区视频免费看| 午夜久久久在线观看| 男女午夜视频在线观看| 一级毛片 在线播放| 精品亚洲成a人片在线观看| 性少妇av在线| 久久久国产欧美日韩av| 又粗又硬又长又爽又黄的视频| 日韩视频在线欧美| 欧美少妇被猛烈插入视频| 国产av一区二区精品久久| 亚洲欧洲日产国产| 熟女av电影| 成人漫画全彩无遮挡| 18禁国产床啪视频网站| 日韩成人av中文字幕在线观看| 人人妻人人爽人人添夜夜欢视频| 啦啦啦中文免费视频观看日本| 老汉色av国产亚洲站长工具| 日日摸夜夜添夜夜爱| 成人免费观看视频高清| 午夜老司机福利剧场| 99国产综合亚洲精品| 婷婷色综合www| 寂寞人妻少妇视频99o| 久久久久网色| 丝袜人妻中文字幕| 国产无遮挡羞羞视频在线观看| 制服诱惑二区| 丝瓜视频免费看黄片| 久久这里只有精品19| 亚洲少妇的诱惑av| 大码成人一级视频| 欧美变态另类bdsm刘玥| 综合色丁香网| 成人亚洲精品一区在线观看| 99久久精品国产国产毛片| 永久网站在线| 少妇 在线观看| 久久99精品国语久久久| 久久久久久久大尺度免费视频| 最黄视频免费看| 黑人巨大精品欧美一区二区蜜桃| 国产精品亚洲av一区麻豆 | 亚洲欧美精品自产自拍| 久久久久精品性色| 只有这里有精品99| 18禁观看日本| 亚洲成国产人片在线观看| 亚洲三级黄色毛片| 青春草亚洲视频在线观看| 尾随美女入室| 午夜福利视频精品| 永久网站在线| 亚洲欧美日韩另类电影网站| 国产精品偷伦视频观看了| a 毛片基地| 日本免费在线观看一区| 精品一区二区免费观看| 一边亲一边摸免费视频| 国产无遮挡羞羞视频在线观看| 亚洲欧美一区二区三区黑人 | 久久久久久人妻| 欧美亚洲 丝袜 人妻 在线| 免费日韩欧美在线观看| 90打野战视频偷拍视频| 亚洲情色 制服丝袜| 男女无遮挡免费网站观看| 国产成人91sexporn| 婷婷成人精品国产| 亚洲精品日韩在线中文字幕| 亚洲av免费高清在线观看| 五月开心婷婷网| 成人影院久久| 午夜福利乱码中文字幕| 久久久久视频综合| 极品少妇高潮喷水抽搐| 少妇被粗大猛烈的视频| 啦啦啦啦在线视频资源| 男的添女的下面高潮视频| 高清欧美精品videossex| 美女午夜性视频免费| av网站在线播放免费| 亚洲欧美成人精品一区二区| 一区二区三区四区激情视频| 精品国产乱码久久久久久男人| 下体分泌物呈黄色| 亚洲天堂av无毛| 丝瓜视频免费看黄片| 成年女人毛片免费观看观看9 | 欧美日韩一级在线毛片| 一个人免费看片子| 国产高清国产精品国产三级| videosex国产| 色婷婷久久久亚洲欧美| 街头女战士在线观看网站| 国产深夜福利视频在线观看| 日韩av免费高清视频| 国产成人一区二区在线| 咕卡用的链子| 日韩av不卡免费在线播放| 黄色 视频免费看| 七月丁香在线播放| 久久久欧美国产精品| 中文字幕av电影在线播放| 在线天堂最新版资源| 亚洲欧美精品综合一区二区三区 | 狂野欧美激情性bbbbbb| av福利片在线| 国产日韩欧美在线精品| 青青草视频在线视频观看| 久久久久久久久久人人人人人人| av女优亚洲男人天堂| 如日韩欧美国产精品一区二区三区| 丝瓜视频免费看黄片| 2018国产大陆天天弄谢| 亚洲成av片中文字幕在线观看 | 中文字幕人妻丝袜一区二区 | 涩涩av久久男人的天堂| 国产片内射在线| 女人久久www免费人成看片| 2021少妇久久久久久久久久久| 18在线观看网站| www.自偷自拍.com| 熟女少妇亚洲综合色aaa.| 精品人妻熟女毛片av久久网站| 美国免费a级毛片| 欧美精品一区二区大全| 久久久久久人人人人人| 国产精品人妻久久久影院| 亚洲国产精品999| 久久精品国产综合久久久| 男的添女的下面高潮视频| 黄色 视频免费看| 免费不卡的大黄色大毛片视频在线观看| 80岁老熟妇乱子伦牲交| 日日爽夜夜爽网站| 亚洲精品aⅴ在线观看| 亚洲国产欧美日韩在线播放| 在线观看三级黄色| 久久久久精品人妻al黑| 女性被躁到高潮视频| 亚洲天堂av无毛| 一级爰片在线观看| 日韩成人av中文字幕在线观看| 你懂的网址亚洲精品在线观看| 国产乱来视频区| 日韩制服骚丝袜av| 18+在线观看网站| 好男人视频免费观看在线| 人成视频在线观看免费观看| 久热久热在线精品观看| 精品午夜福利在线看| 99re6热这里在线精品视频| 我要看黄色一级片免费的| 青草久久国产| 久久久a久久爽久久v久久| 亚洲情色 制服丝袜| 你懂的网址亚洲精品在线观看| 天堂俺去俺来也www色官网| 精品国产一区二区三区四区第35| 啦啦啦中文免费视频观看日本| 男女免费视频国产| 香蕉精品网在线| 一级片'在线观看视频| 九草在线视频观看| 人妻少妇偷人精品九色| 一区二区av电影网| 亚洲精华国产精华液的使用体验| 一级毛片我不卡| 天天躁夜夜躁狠狠久久av| 久久人人97超碰香蕉20202| 97在线视频观看| 亚洲av电影在线进入| 久久人人爽人人片av| 99热网站在线观看| 欧美黄色片欧美黄色片| 2021少妇久久久久久久久久久| 亚洲色图 男人天堂 中文字幕| 波多野结衣av一区二区av| 欧美精品av麻豆av| 丝袜美腿诱惑在线| 亚洲av综合色区一区| 国产成人精品婷婷| 国产成人精品福利久久| 人妻少妇偷人精品九色| 国产一区二区在线观看av| 一级爰片在线观看| www.熟女人妻精品国产| 1024香蕉在线观看| 久久精品久久精品一区二区三区| 亚洲av免费高清在线观看| 男女下面插进去视频免费观看| 人妻系列 视频| 国产欧美日韩综合在线一区二区| 波多野结衣av一区二区av| 搡老乐熟女国产| 黄色配什么色好看| av国产久精品久网站免费入址| 狠狠婷婷综合久久久久久88av| 久久精品夜色国产| 精品国产乱码久久久久久小说| 伊人久久国产一区二区| 熟女少妇亚洲综合色aaa.| 宅男免费午夜| 亚洲 欧美一区二区三区| 久久女婷五月综合色啪小说| 国产精品嫩草影院av在线观看| 亚洲精品日韩在线中文字幕| 免费看av在线观看网站| 亚洲综合色惰| 成人午夜精彩视频在线观看| 一区二区三区四区激情视频| 男女免费视频国产| 亚洲av综合色区一区| 国产精品亚洲av一区麻豆 | 国产免费又黄又爽又色| 2018国产大陆天天弄谢| av在线老鸭窝| 久久久精品94久久精品| 蜜桃在线观看..| 大片免费播放器 马上看| 成人毛片60女人毛片免费| 久久人人爽人人片av| 婷婷色综合大香蕉|